Sanofi Urges 10th Circ. To Revive EpiPen Antitrust Case
Sanofi-Aventis US LLC told the Tenth Circuit that it deserves to have a jury hear its allegations that Mylan illegally blocked a potential competitor to its emergency allergy treatment EpiPen, contending...To view the full article, register now.
Already a subscriber? Click here to view full article